Abstract
Results of large-scale studies (QUIET, HOPE, EUROPA, PEACE, CAMELOT), devoted to assessment of the role of ACE inhibitors in treatment of patients with stable form of ischemic heart disease without heart failure are analyzed. Different efficacy of the representatives of this class toward risks of coronary events development and cerebral-vascular complications is shown, as well as the overall mortality risk due to cardiovascular reasons. Favorable therapeutic effects of inhibiting RAS activity in patients without left ventricle dysfunction are demonstrated in studies EUROPA with perindopril 8 mg, and HOPE with ramipril 10 mg. That became the ground of inclusion of these drugs into recommendations for treatment of all patients with ischemic heart disease after myocardial infarction, in addition to antiplatelet, lipid reducing remedies and beta-blockers.
Highlights
Иингибиторы ангиотензин-превращающего фермента (АПФ) у больных стабильной ишемическая болезнь сердца (ИБС) без сердечной недостаточности: эффекты класса и эффективность его представителей Ю.А
Favorable therapeutic effects of inhibiting RAS activity in patients without left ventricle dysfunction are demonstrated in studies EUROPA with perindopril 8 mg, and HOPE with ramipril 10 mg
That became the ground of inclusion of these drugs into recommendations for treatment of all patients with ischemic heart disease after myocardial infarction, in addition to antiplatelet, lipid reducing remedies and beta-blockers
Summary
Иингибиторы АПФ у больных стабильной ИБС без сердечной недостаточности: эффекты класса и эффективность его представителей Ю.А. Проанализированы результаты крупномасштабных исследований (QUIET, HOPE, EUROPA, PEACE, CAMELOT) по оценке роли ингибиторов АПФ в лечении больных стабильной ИБС без сердечной недостаточности. ACE inhibitors in patients with ischemic heart disease without heart failure: class effects and efficacy of its representatives Y.A. Karpov. Results of large-scale studies (QUIET, HOPE, EUROPA, PEACE, CAMELOT), devoted to assessment of the role of ACE inhibitors in treatment of patients with stable form of ischemic heart disease without heart failure are analyzed. Рациональная Фармакотерапия в Кардиологии 2005;No1 шенным АД и при наличии признаков сердечной недостаточности (СН), после перенесенного ИМ можно говорить о класс-эффекте при этих заболеваниях, тем более, что основным гемодинамическим действием ингибиторов АПФ, например у больных АГ, и, соответственно, выбора дозы, является как раз присущее им всем снижение АД
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
